Exhibit 1013 (c)


		
			﻿
		

		
			                          Exhibit 10.13(c)
		

		
			﻿
		

		
			﻿
		

		
			Second Amendment to the Exclusive IP License Agreement for RQ-00000005 between Aratana Therapeutics Inc. and RaQualia Pharma Inc.
		

		
			﻿
		

		
			This is the Second Amendment (“Second Amendment”) to the Exclusive IP License Agreement for RQ-00000005 dated December 27, 2010 (the “Agreement”) between Aratana Therapeutics Inc., a Delaware corporation (“Licensee”) and RaQualia Pharma Inc., a Japanese corporation (“Licensor”), and is made and entered into between Licensee and Licensor on January 2nd, 2017 (the “Second Amendment Effective Date”). Licensee and Licensor are referred to herein individually as a “Party” and collectively as the “Parties”.
		

		
			RECITALS
		

		
			WHEREAS, the Parties have entered into the Agreement, pursuant to which the Licensor granted Licensee an exclusive worldwide license to RQ-00000005 Technology (as defined in the Agreement);
		

		
			WHEREAS,  the Parties desire to amend the disclosure provisions of the Agreement to reduce the frequency of required meetings.
		

		
			NOW, THEREFORE, in consideration of the mutual covenants set forth herein and for other consideration, the receipt and sufficiency of which are hereby acknowledged, the Parties hereby agree as follows:
		

		
			﻿
		

		
			AGREEMENT
		

		
			﻿
		

		
			Section 6.1 of the Agreement is hereby deleted and replaced as follows:
		

		
			6.1 Disclosure. Each Party will provide twice yearly as of “January 1st and July 1st,  a brief report of any Improvements created, conceived, or reduced to practice since the last report, including a list and description of all patent applications pertaining to the Improvements filed since the last report.  In addition, Licensor and Licensee shall meet once per year during the term of this Agreement at a time and place mutually agreed upon between the Parties, which may be telephonically or in person, to disclose Licensor and Licensee Improvements.  In the event there have been no Licensor or Licensee Improvements since the prior meeting, as notified by each Party in writing, no such meeting shall be required.
		

		

		

		 

 


		

			    

		




		
		

		
			﻿
		

		
			IN WITNESS WHEREOF, the Parties have caused this Amendment to the Agreement to be executed by their authorized representatives.
		

			
					
						﻿

					
						 

					
						RaQualia Pharma, Inc.  by:

					
					
						 

					
						 

					
						 

					
						 

					
						/s/ Naoki Tani

				
	
					
						Signature of authorised signatory

					
						 

					
						 

					
						Naoki Tani

				
	
					
						﻿

					
					
						Name of authorised signatory

					
						 

					
						President and CEO__________________________

					
						Title

					
						 

					
						__2017/2/09_______________________________

					
						Date

					
						 

					
						 

					
						 

					
						 

					
						 

				



		
			ARATANA therapeutics, INC by:
		

			
					
						﻿

					
						 

					
						 

					
						 

					
					
						 

					
						_/s/ Steven St. Peter_________________________

					
						Signature of authorised signatory

					
						 

					
						 

					
						Steven St. Peter

				
	
					
						Name of authorised signatory

					
						 

					
						CEO____________________________________

					
						Title

					
						 

					
						1/3/2017________________________________

					
						Date

					
						 

					
						 

				



		
			﻿
		

		
			﻿
		

		 


		

			 

		


		

			2